![ECOG-ACRIN logo[19516]275×75](https://blog-ecog-acrin.org/wp-content/uploads/2021/03/ECOG-ACRIN-logo19516275x75.png)
October 17, 2024
Summaries of recently published ECOG-ACRIN research results
September 17, 2024
Summaries of recently published ECOG-ACRIN research results
August 14, 2024
Thoughts on the evolving clinical cancer research environment—and practice-changing results in acute lymphoblastic leukemia
August 14, 2024
A Scientific Member of ECOG-ACRIN since 2012
August 14, 2024
Summaries of recently published ECOG-ACRIN research results
July 3, 2024
Summaries of recently published ECOG-ACRIN research results
June 11, 2024
This phase 2 study is testing two variations of the triplet combination of azacitidine, venetoclax, and gilteritinib compared to standard therapy
May 1, 2024
Summaries of recently published ECOG-ACRIN research results
April 9, 2024
Summaries of recently published ECOG-ACRIN research results
October 19, 2023
These four leukemia treatment trials and an observational study of myelodysplastic syndromes are all open and enrolling patients
August 25, 2023
Summaries of recently published ECOG-ACRIN research results
February 10, 2023
The phase 3 E1910 clinical trial provides strong evidence for adding immunotherapy to standard front-line consolidation chemotherapy